UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs Ltd reported Q3 FY26 (quarter ended 31 Dec 2025) revenue from operations of about ₹3.78 crore, down sharply from ₹5.51 crore in the same quarter last year (around 31% YoY decline). Profit after tax for the quarter stood at roughly ₹5.22 lakh versus ₹12.70 lakh in Q3 FY25, a decline of nearly 59% YoY. For the nine months ended Dec 2025, revenue was ₹15.69 crore vs ₹17.17 crore in the same period last year. The weakness is linked to a part of the company's manufacturing facility being under suspension since 11 Feb 2025 following FDA directions; the suspension was lifted on 28 Nov 2025, allowing operations to resume in that section.
Short-term: Weak quarter with sharp revenue and profit decline as the suspended facility hurt production for most of the period. Medium-term: Resumption of operations from late Nov 2025 should help revenue and margins recover in coming quarters, but investors should watch whether full normalcy is restored.